Page last updated: 2024-12-07

1,3-bis(4-amidinophenoxy)-2-(4-amidinophenoxymethyl)ethylpropane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3-bis(4-amidinophenoxy)-2-(4-amidinophenoxymethyl)ethylpropane is a **synthetic compound** that is not commonly known or researched. It is not a recognized chemical entity in standard databases or scientific literature.

It's possible that:

* **The name is incorrect or misspelled:** There might be a typographical error in the name, leading to an unknown compound.
* **It's a novel compound under development:** The compound might be a new discovery or a research project in early stages, not yet published or widely known.
* **It's a specific variation of a known compound:** It could be a derivative of a known molecule with slight modifications in its structure.

**To find more information, you would need:**

* **Verify the name:** Double-check the spelling and the chemical formula to ensure it's correct.
* **Search for similar compounds:** Look for related structures or compounds with similar names and functionalities.
* **Contact research groups:** Reach out to researchers in the field where this compound might be relevant to see if they have any information.

Without more details, it's impossible to determine its potential importance in research. However, the presence of multiple amidine groups suggests it could have applications in fields such as:

* **Drug discovery:** Amidines are known for their biological activity and can interact with various targets in the body.
* **Material science:** They can be used in the development of polymers and other materials with specific properties.
* **Biochemistry:** They could be used as probes or reagents in biological research.

Remember, it's important to rely on reliable sources of information, such as peer-reviewed scientific journals, chemical databases, and reputable research institutions.

1,3-bis(4-amidinophenoxy)-2-(4-amidinophenoxymethyl)ethylpropane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130770
MeSH IDM0200982

Synonyms (8)

Synonym
1,3-bis(4-amidinophenoxy)-2-(4-amidinophenoxymethyl)ethylpropane
1-(p-amidinophenoxy)-2,2-bis(p-amidinophenoxymethyl)-butane
115044-37-6
benzenecarboximidamide, 4,4'-((2-((4-(aminoiminomethyl)phenoxy)methyl)-2-ethyl-1,3-propanediyl)bis(oxy)bis-
tapb
4-[3-(4-carbamimidoylphenoxy)-2-[(4-carbamimidoylphenoxy)methyl]pentoxy]benzenecarboximidamide
4,4'-[{2-[(4-carbamimidoylphenoxy)methyl]pentane-1,3-diyl}bis(oxy)]di(benzene-1-carboximidamide)
DTXSID20921602

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"To compare the effect of ultrasound-guided transversus abdominis plane block (TAPB) combined with patient-controlled intravenous analgesia (PCIA) and PCIA alone on analgesia after laparoscopic cholecystectomy (LC)."( Effect of Ultrasound-Guided Transversus Abdominis Plane Block Combined with Patient-Controlled Intravenous Analgesia on Postoperative Analgesia After Laparoscopic Cholecystectomy: a Double-Blind, Randomized Controlled Trial.
Dai, L; Ling, X; Qian, Y, 2022
)
0.72
"Ultrasound-guided TAPB combined with PCIA was an effective and safe perioperative analgesic technique for patients undergoing LC compared to PCIA only."( Effect of Ultrasound-Guided Transversus Abdominis Plane Block Combined with Patient-Controlled Intravenous Analgesia on Postoperative Analgesia After Laparoscopic Cholecystectomy: a Double-Blind, Randomized Controlled Trial.
Dai, L; Ling, X; Qian, Y, 2022
)
0.72
"This review aimed to conduct a meta-analysis of published randomized controlled studies (RCTs) comparing the effectiveness of dexmedetomidine (DEX) combined with ropivacaine versus single ropivacaine in transversus abdominis plane block (TAPB) for postoperative analgesia after laparoscopic cholecystectomy (LC)."( Analgesic Effects of Ropivacaine Combined With Dexmedetomidine in Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Cholecystectomy: A Systematic Review and Meta-Analysis.
Sun, W; Zhu, M, 2023
)
0.91
"Five electronic database systems were searched for RCTs on the effects of DEX combined with ropivacaine (joint group) and single ropivacaine on postoperative analgesia in LC."( Analgesic Effects of Ropivacaine Combined With Dexmedetomidine in Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Cholecystectomy: A Systematic Review and Meta-Analysis.
Sun, W; Zhu, M, 2023
)
0.91
" The results showed that compared with single ropivacaine, DEX combined with ropivacaine in TAPB had better analgesia and lighter sedative effect in patients after LC."( Analgesic Effects of Ropivacaine Combined With Dexmedetomidine in Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Cholecystectomy: A Systematic Review and Meta-Analysis.
Sun, W; Zhu, M, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (14.81)18.2507
2000's2 (7.41)29.6817
2010's0 (0.00)24.3611
2020's21 (77.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.61 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (37.04%)5.53%
Reviews4 (14.81%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (48.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]